Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

By D. Jorenby, J. Hays, N. Rigotti, S. Azoulay, E. Watsky, K. Williams, C. Billing, J. Gong, K. Reeves. 2006

1,321 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Ca2+ Permeability of the (α4)3(β2)2 Stoichiometry Greatly Exceeds That of (α4)2(β2)3 Human Acetylcholine Receptors (2006, background): “The newly approved drug for smoking cessation, varenicline, is believed to act like cytisine as a partial agonist on 4 2 AChRs in oocytes and on dopaminergic neurons (Coe et al., 2005; Jorenby et al., 2006).”
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction (2014, background): “For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”